Advertisement
News
Subscribe to MDT Magazine News

Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business

April 27, 2011 12:33 am | by Bio-Medicine.Org | Comments

NEW BRUNSWICK, N.J. and WEST CHESTER, Pa., April 27, 2011 /- Johnson & Johnson (NYSE: JNJ ), the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc. (SWX:SYST.VX), a premier global manufacturer of orthopaedic devices, today announced...

TOPICS:

Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results

April 26, 2011 11:33 pm | by Bio-Medicine.Org | Comments

SEATTLE, April 27, 2011 /- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported accomplishments and financial results for the first quarter ended March 31, 2011. "In the first quarter, we raised $50 million through two financings, advanced pixantrone into...

TOPICS:

Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011

April 26, 2011 5:37 pm | by Bio-Medicine.Org | Comments

STEWARTVILLE, Minn., April 26, 2011 /- Rochester Medical Corporation (NASDAQ: ROCM ) will announce quarterly results after financial markets close on Thursday, May 5, 2011.  The Company will then hold a quarterly conference call to discuss its earnings report.  The call will...

TOPICS:
Advertisement

JumpStart Ventures Invests in Cleveland-based SPR Therapeutics

April 26, 2011 5:37 pm | by Bio-Medicine.Org | Comments

CLEVELAND, April 26, 2011 /- JumpStart Ventures , a nonprofit that invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in SPR™ Therapeutics . The one-year-old Beachwood, Ohio-based company is...

TOPICS:

Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease

April 26, 2011 5:36 pm | by Bio-Medicine.Org | Comments

INDIANAPOLIS and MINNEAPOLIS, April 26, 2011 /- Eli Lilly and Company (NYSE: LLY ) and Medtronic, Inc. (NYSE: MDT ) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new...

TOPICS:

Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy

April 26, 2011 5:36 pm | by Bio-Medicine.Org | Comments

BOCA RATON, Fla., April 26, 2011 /- The Premier healthcare alliance, a network of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites working together to achieve high quality, cost-effective care, has awarded Sensus Healthcare, Inc. , the leading provider of FDA-approved...

TOPICS:

Renewable Fuel Standard Provides Market Space and Predictable Price for Advanced Biofuels

April 26, 2011 5:34 pm | by Biotechnology Industry Organization | Comments

WASHINGTON, D.C. (Tuesday, April 19, 2011) - The federal Renewable Fuel Standard provides the stable market support and pricing system necessary to attract private investment to the development of advanced biofuels, according to a new policy white paper published by the Biotechnology...

TOPICS:

Mosby's eLearning and the ASHI introduce ACLS Blended Learning Solution

April 26, 2011 5:34 pm | by EurekAlert | Comments

(Elsevier) Mosby's eLearning, a pioneer in providing eLearning solutions to more than 1,300 healthcare organizations, and the American Safety & Health Institute (ASHI) today introduced the Advanced Cardiac Life Support (ACLS) Blended Learning Solution, a training certification solution...

TOPICS:
Advertisement

Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Sm...

April 26, 2011 5:34 pm | by Bio-Medicine.Org | Comments

VIENNA and BETHLEHEM, Pa., April 26, 2011 /- In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research (CESAR) announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management (TDM) with subsequent...

TOPICS:

Mindray to Report First Quarter 2011 Financial Results on May 9, 2011

April 26, 2011 5:33 pm | by Bio-Medicine.Org | Comments

SHENZHEN, China, April 26, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR ), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will report its financial results for the first quarter ended March 31,...

TOPICS:

Universal Health Services 1Q profit surges

April 26, 2011 4:46 pm | by The Associated Press | Comments

Hospital operator Universal Health Services Inc. said Tuesday that its first-quarter profit rose 59 percent on higher revenue from behavioral health facilities that it gained with its buyout of Psychiatric Solutions Inc.Net income climbed to $114.2 million, or $1.15 per share, from $71.8...

Life Technologies reports 1Q profit boost

April 26, 2011 2:45 pm | by The Associated Press | Comments

Life Technologies Corp., a life sciences and medical research tools company, said Tuesday its first-quarter net income rose just 2 percent as the March 11 earthquake and tsunami in Japan restrained revenue.Meanwhile, the company set its 2011 profit guidance below Wall Street expectations. The...

Earnings Preview: Aetna reports on 1Q Thursday

April 26, 2011 2:45 pm | by The Associated Press | Comments

Aetna Inc., the third-largest health insurer, reports its first-quarter results Thursday before the market opens.WHAT TO WATCH FOR: Whether better pricing and a slowdown in health care use have continued. Both helped the Hartford, Conn., managed care company post a 30 percent jump in net income...

Motor protein may offer promise in ovarian cancer treatment

April 26, 2011 1:37 pm | by EurekAlert | Comments

(Penn State) A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.

TOPICS:

Antibiotic may prove beneficial to preterm infant lung health

April 26, 2011 12:38 pm | by EurekAlert | Comments

(University of Kentucky) A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia (BPD).

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading